 Heidelberg, Germany, April 15, 2021 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2020 and provided an update on clinical and corporate progress. 